EMA denies adaptive licensing project 'slowing or closing down'; calls for more applications
This article was originally published in SRA
Executive Summary
The European Medicines Agency said yesterday it wanted to quash a rumor that its in-demand adaptive licensing pilot project was slowing or closing down. "We are very much open to further submissions" from drug companies that want to take part in the initiative, a UK regulator involved in the pilot said.
You may also be interested in...
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
Moment Of Truth For Seven EU Filings; Cytokinetics To Make Its Case For Heart Failure Drug
The CHMP, the European Medicines Agency’s human medicines committee, will this week decide whether a range of new medicines merit being approved.
EMA Probe Finds No Link Between GLP-1s And Suicidal Thoughts & Actions
After reviewing the evidence from non-clinical studies, clinical trials, post-marketing surveillance data and other studies, the European Medicines Agency said there was no need to update the product information for 11 diabetes and weight management drugs.